PetVivo Holdings Inc (PETV) Q1 2026 Earnings Report

PetVivo reported a modest quarterly revenue base in QQ1 2026 (quarter ended June 30, 2025) of $297,500, up 141% YoY but down about 49% sequentially, highlighting the early-stage nature of the business and the sensitivity of sales to distributor channel activity and new product introductions. Gross profit was $186,726 (gross margin ~63%), with the margin pressured by the initial product mix shift to PrecisePRP alongside Spryng. Operating expenses declined 9% QoQ to $2.03 million as part of an ongoing cost-reduction program, contributing to a reduced operating loss of $1.84 million. Net loss widened to $2.31 million, or a loss of $0.09 per basic/diluted share, reflecting ongoing investment in R&D, sales expansion, and go-to-market activities, as well as one-time lease terminations and inventory build related to new product lines. cash, liquidity, and balance sheet health improved meaningfully in the quarter: ending cash of $3.30 million vs. $0.23 million at the prior year-ago period, supported by net financing proceeds of $4.71 million in the last 90 days of the quarter, and total liabilities decreasing ~39% YoY to $3.16 million. Management underscored a strategic emphasis on Spryng adoption, the PrecisePRP collaboration with VetStem, and a broader pipeline of partnerships and technologies (AI, biomaterials, diagnostics). They also signaled a longer-term growth trajectory supported by expanding domestic and international distribution, and a push into high-growth markets such as equine and companion animals. Management projections emphasize continued sales momentum through fiscal 2026 and beyond, with catalysts including a commercial-grade pet AI platform beta and planned Q3 2025 launch. While the near-term path remains capital-intensive with ongoing operating losses, the company has strengthened liquidity and capital structure, improving financial flexibility to fund growth initiatives.